BR112013013457A2 - métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições - Google Patents
métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composiçõesInfo
- Publication number
- BR112013013457A2 BR112013013457A2 BR112013013457A BR112013013457A BR112013013457A2 BR 112013013457 A2 BR112013013457 A2 BR 112013013457A2 BR 112013013457 A BR112013013457 A BR 112013013457A BR 112013013457 A BR112013013457 A BR 112013013457A BR 112013013457 A2 BR112013013457 A2 BR 112013013457A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- identifying
- parkinson
- predicting
- assay
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41820810P | 2010-11-30 | 2010-11-30 | |
| PCT/US2011/062468 WO2012075046A1 (en) | 2010-11-30 | 2011-11-29 | Assays and biomarkers for lrrk2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013013457A2 true BR112013013457A2 (pt) | 2017-07-11 |
Family
ID=45217723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013013457A BR112013013457A2 (pt) | 2010-11-30 | 2011-11-29 | métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2646819A1 (pt) |
| JP (1) | JP2014504362A (pt) |
| KR (1) | KR20130121903A (pt) |
| CN (1) | CN103348243A (pt) |
| BR (1) | BR112013013457A2 (pt) |
| CA (1) | CA2818428A1 (pt) |
| MX (1) | MX2013005801A (pt) |
| RU (1) | RU2013129818A (pt) |
| WO (1) | WO2012075046A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6189948B2 (ja) | 2012-06-29 | 2017-08-30 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規な４−（置換アミノ）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン |
| WO2014059052A1 (en) * | 2012-10-09 | 2014-04-17 | Uab Research Foundation | Methods and compositions for diagnosis and treatment of parkinson's disease and parkinsonism |
| US9582909B2 (en) * | 2012-11-15 | 2017-02-28 | Shimadzu Corporation | Chromatograph mass spectrometry data processing device |
| WO2017156493A1 (en) | 2016-03-11 | 2017-09-14 | Denali Therapeutics Inc. | Compounds, compositions, and methods |
| US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
| RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| CN105331721A (zh) * | 2015-11-27 | 2016-02-17 | 首都医科大学宣武医院 | 检测pd致病基因突变的方法，及其引物、试剂盒 |
| SI3472153T1 (sl) | 2016-06-16 | 2022-01-31 | Denali Therapeutics Inc. | Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj |
| RU2761436C1 (ru) | 2017-11-17 | 2021-12-08 | Целликс Био Прайвет Лимитед | Композиции и способы лечения нарушений со стороны органа зрения |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2009101384A (ru) | 2006-06-20 | 2010-07-27 | Новартис АГ (CH) | Биомаркеры прогрессирования болезни альцгеймера |
| WO2008091799A2 (en) * | 2007-01-22 | 2008-07-31 | The Trustees Of Columbia University In The City Of New York | Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants |
| GB0706709D0 (en) * | 2007-04-05 | 2007-05-16 | Medical Res Council | Methods |
| US20100175140A1 (en) * | 2008-12-19 | 2010-07-08 | The Johns Hopkins University | Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies |
| WO2010129053A2 (en) * | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
| US8367349B2 (en) * | 2010-04-19 | 2013-02-05 | Medical Research Council | Methods for identifying modulators of LRRK2 |
-
2011
- 2011-11-29 RU RU2013129818/15A patent/RU2013129818A/ru not_active Application Discontinuation
- 2011-11-29 KR KR1020137016950A patent/KR20130121903A/ko not_active Application Discontinuation
- 2011-11-29 WO PCT/US2011/062468 patent/WO2012075046A1/en active Application Filing
- 2011-11-29 MX MX2013005801A patent/MX2013005801A/es not_active Application Discontinuation
- 2011-11-29 CN CN2011800663409A patent/CN103348243A/zh active Pending
- 2011-11-29 BR BR112013013457A patent/BR112013013457A2/pt not_active IP Right Cessation
- 2011-11-29 JP JP2013542113A patent/JP2014504362A/ja active Pending
- 2011-11-29 CA CA2818428A patent/CA2818428A1/en not_active Abandoned
- 2011-11-29 EP EP11793632.8A patent/EP2646819A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2818428A1 (en) | 2012-06-07 |
| CN103348243A (zh) | 2013-10-09 |
| WO2012075046A1 (en) | 2012-06-07 |
| JP2014504362A (ja) | 2014-02-20 |
| RU2013129818A (ru) | 2015-01-10 |
| EP2646819A1 (en) | 2013-10-09 |
| MX2013005801A (es) | 2013-07-17 |
| WO2012075046A9 (en) | 2012-09-13 |
| KR20130121903A (ko) | 2013-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013013457A2 (pt) | métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| BRPI1007321A2 (pt) | métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo. | |
| BR112012031389A2 (pt) | método para prever os resultados clínicos para pacientes com melanoma usando células de melanoma circulantes no sangue | |
| BRPI0720116B8 (pt) | método para determinar uma suscetibilidade à arritmia cardíaca ou acidente vascular cerebral em um indivíduo humano, uso de uma sonda de oligonucleotídeo, e, aparelho para determinar um indicador genético para a arritmia cardíaca e/ou acidente vascular cerebral em um indivíduo humano | |
| BRPI1010648A2 (pt) | métodos para o diagnóstico de distúrbios oncológicos usando transferidores epimetabólicos, moléculas intracelulares multidimensionais ou influenciadores ambientais | |
| BR112013006683A2 (pt) | diagnóstico de câncer de mama | |
| WO2011135459A3 (en) | Methods and devices for predicting treatment efficacy | |
| WO2012078623A3 (en) | Biomarkers for monitoring treatment of neuropsychiatric diseases | |
| MX343327B (es) | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. | |
| BR112013010015A2 (pt) | aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos | |
| BR112013000745A2 (pt) | "método para diagnosticar ou detectar câncer colorretal em um individuo, método de tratamento e método para monitorar a eficacia de tratamento de câncer colorretal em um indivíduo" | |
| BRPI0819410A2 (pt) | "dispositivo com múltiplas camadas para detecção de analitos" | |
| BRPI0915619A2 (pt) | métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra | |
| WO2008138578A3 (en) | Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy | |
| BR112015003046A2 (pt) | sistema de neurofeedback, processador de sinal para determinação de uma característica do sinal do sinal do biofeedback medido, método para provisão de um usuário com o neurofeedback e programa de computador. | |
| ATE531820T1 (de) | Gesundheitszustandstest | |
| BR112013001752A2 (pt) | método de detectar doenças ou condições usando células fagocídicas | |
| EP3498729A3 (en) | Therapeutic targets for alzheimer's disease | |
| BRPI0820693A2 (pt) | Fotoestabilidade aumentada de avobenzona na presença de óxido de zinco usando emulsificantes à base de fosfato | |
| BR112014031414A2 (pt) | métodos de detectar doenças ou condições utilizando células doentes circulantes | |
| EP2178440A4 (en) | ANALYSIS BY OPTICAL COHERENCE TOMOGRAPHY | |
| IT1399590B1 (it) | Apparato e kit per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti | |
| WO2010045490A3 (en) | Human biomarker hypermapping for depressive disorders | |
| BR112013016071A2 (pt) | "métodos, dispositivo e kit de diagnóstico de diabete e uso de glioxilato ou um agente de detecção para glioxilato" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |